|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25显示文摘堵住抗体 ipilimumab 的细胞毒素的 T 淋巴细胞 antigen-4 (CTLA-4 ) 在很少的病人导致变形黑瘤的调停免疫者的长期的控制。尽管 ipilimumab 无疑经由 immunostimulation 施加它的治疗学的效果,这样远的临床上有用的、 immunologically 相关的 biomarkers 预言治疗效率是逃犯的。这里,我们显示出 IL-2 的那中立化或堵住 α并且 βIL-2 受体的子单元(CD25 和 CD122,分别地) 否则在现出症状之前的潜的老鼠模型由 CTLA-4 封锁导致了,废除了 antitumor 效果和 intratumoral T 受动器对规章的房间(Tregs ) 的比率的伴随的改进,它是。CTLA-4 封锁导致了在失去了 FoxP3 表示并且在 regressing 肿瘤积累了的 IL-2-producing 受动器房间与伴随物上升表示 Lag3, ICOS, IL-10 和 Egr2 的一个镇压 CD4 + T 房间子集的减小。当 recombinant IL-2 改进了 CTLA-4 封锁的治疗学的功效时,圈套 IL-2 受体 α(IL-2Rα, sCD25 ) 禁止了 CTLA-4 的 anticancer 效果封锁。在收到 ipilimumab 的 262 个变形黑瘤病人, sCD25 的基线浆液集中代表了全面幸存的独立指示物,与预言到治疗的抵抗的高水平。总的来说,这些结果解开为在 CTLA-4 的 anticancer 活动的 IL-2 和 IL-2 受体的一个角色封锁。重要地,我们的学习提供第一 immunologically 相关的 biomarker,也就是提高的浆液 sCD25,那与黑瘤在病人预言抵抗到 CTLA-4 封锁。 | Dalil Hannani Marie Vetizou David Enot Sylvie Rusakiewicz Nathalie Chaput David Klatzmann Melanie Desbois Nicolas Jacquelot Nadege Vimond Salem Chouaib Christine Mateus James P Allison Antoni Ribas Jedd D Wolchok Jianda Yuan Philip Wong Michael Postow Andrzej Mackiewicz Jacek Mackiewicz Dirk Schadendorff Dirk Jaeger Alan J Korman Keith Bahjat Michele Maio Luana Calabro Michele WL Teng Mark J Smyth Alexander Eggennont Caroline Robert Guido Kroemer Laurence Zitvogel | 2015 | Cell Research2015，25，2： | 14 |
| 2 | Immune Modulation in Cancer with Antibodies显示文摘 | David B. Page Michael A. Postow Margaret K. Callahan James P. Allison Jedd D. Wolchok | 2014 | Annual Review of Medicine2014，，： | 2 |
| 3 | Antibody therapy of cancer 显示文摘 | Scott AM Wolchok JD Old LJ | 2012 | Nat Rev Cancer2012，12，： | 1 |
| 4 | KIT as a therapeutic target in metastatic melanoma显示文摘 | Carvajal RD Antonescu CR Wolchok JD | 2011 | JAMA2011，305，22： | 1 |
| 5 | Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas显示文摘 | Piro Lito Christine A. Pratilas Eric W. Joseph Madhavi Tadi Ensar Halilovic Matthew Zubrowski Alan Huang Wai Lin Wong Margaret K. Callahan Taha Merghoub Jedd D. Wolchok Elisa de Stanchina Sarat Chandarlapaty Poulikos I. Poulikakos James A. Fagin Neal Rose | 2012 | Cancer Cell2012，，5： | 1 |
| 6 | KIT as a therapeutic target in metastatic melanoma 显示文摘 | Carvajal RD Antonescu CR Wolchok JD | 2011 | JAMA2011，305，22： | 1 |
| 7 | Nivolumab plus ipilimumab in advanced melanoma显示文摘 | Wolchok JD Kluger H Callahan MK | 2013 | N Engl J Med2013，369，2： | 1 |
| 8 | Guidelines for the evaluation of immune therapy activity in solid tumors:im- mune-related response criteria显示文摘 | WOLCHOK J D HOOS A O DAY S | 2009 | Clin Cancer Res2009，15，23： | 1 |
| 9 | KIT as a therapeutic target in metastatic melanoma显示文摘 | Carvajal RD Antoneseu CR Wolchok JD | 2011 | JAMA2011，305，： | 1 |
| 10 | Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria显示文摘 | Wolchok JD Hoos A O'Day S | 2009 | Clin Cancer Res2009，15，23： | 1 |
| 11 | Nivolurnab plus ipilimumab in advanced melanoma显示文摘 | Wolchok JD Kluger H Callahan MK | 2013 | N Engl J Ailed2013，369，2： | 1 |
| 12 | Guidelines for the evaluation of immune therapy activity in solid tumors:Immune-related response criteria显示文摘 | Wolchok JD Hoos A 0'Day S | 2009 | Clin Cancer Res2009，15，： | 1 |
| 13 | Combined nivolumab and ipilimumab or monotherapy in untreated melanoma 显示文摘 | Larkin J Hodi FS Wolchok JD | 2015 | N Engl Med2015，373，13： | 1 |
| 14 | Anti-CTLA-4 antibody therapy : Immune monitoring during clinical development of a novel immunotherapy 显示文摘 | Callahan MK Wolchok JD Allison JP | 2010 | Semin Oncol2010，37，5： | 1 |
| 15 | Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double - blind, multicentre, phase 2, dose - ranging study显示文摘 | WOLCHOK J D NEYNS B LINETYE G | 2010 | Lancet Oneol2010，11，2： | 1 |
| 16 | Combining cancer immunotherapy and targeted therapy 显示文摘 | Ribas A Wolchok J D | 2013 | Current opinion in immunology2013，25，2： | 1 |
| 17 | Nivolumab plus ipilimumab in advanced melanoma 显示文摘 | WOLCHOK JD KLUGER H CALLAHAN MK | 2013 | N Engl JMed2013，369，2： | 1 |
| 18 | Baseline tu- mor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475显示文摘 | Richard W J Jeroen ES Wolchok JD | 2014 | J Clin Oncol2014，32，5： | 1 |
| 19 | Myeloid - derived sup-pressor sells and the efficacy of CD8 + T - cell immunotherapy显示文摘 | Lesokhin AM Merghoub T Wolchok JD | 2013 | Oncoimmunology2013，2，22： | 1 |
| 20 | The abscopal effectassociated with a systemic antimelanoma immune response 显示文摘 | Stamell EF Wolchok JD Gnjatic S | 2013 | Int J Radiat Oncol Biol Phys2013，85，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员